Key Drivers
- Liquidity Strength
- Persistent Losses
- Negative Cash Flow
AIAI Summary
Heartflow now looks credible on demand and clinical adoption, but the investment case has shifted to whether its 48% growth, 82% gross margin, and $251.5M cash pile can translate into durable profitability and positive free cash flow before its still-rich 12.4x sales valuation loses patience.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Strength
- •Persistent Losses
- •Negative Cash Flow
HTFL has a strong balance sheet and low debt risk, but persistent losses, negative cash flow, and a still-demanding valuation mean the investment case depends on a sustained operational turnaround.
Price Behavior
Key Price Behavior Insights:
- •Breakout strength
- •Overbought extension
- •Support hold
HTFL surged from $24.88 to $42.08 over the last month, breaking above the $27-$31 zone with higher highs/higher lows, but the move is now stretched and needs to hold $31.01 and $27.2-$29.4 to keep the bullish trend intact.
Very fast, steep rally from $24.88 to $42.08 suggests short-term pullback risk
Sentiment & News
Key News Insights:
- •Revenue surge
- •Smaller loss
- •Raised guidance
HeartFlow reported strong Q2 2026 results with revenue up 48% to $64.1 million, a much smaller loss than last year, and raised full-year guidance as adoption of its core diagnostic products continued to expand.
The results suggest improving execution and growing demand for HeartFlow's offerings, which is a positive signal for the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings